Annual CFO
-$96.51 M
-$19.41 M-25.17%
December 31, 2023
Summary
- As of February 12, 2025, XFOR annual cash flow from operations is -$96.51 million, with the most recent change of -$19.41 million (-25.17%) on December 31, 2023.
- During the last 3 years, XFOR annual CFO has fallen by -$37.69 million (-64.09%).
- XFOR annual CFO is now -792.31% below its all-time high of -$10.82 million, reached on December 31, 2015.
Performance
XFOR Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$34.03 M
-$3.75 M-12.40%
September 30, 2024
Summary
- As of February 12, 2025, XFOR quarterly cash flow from operations is -$34.03 million, with the most recent change of -$3.75 million (-12.40%) on September 30, 2024.
- Over the past year, XFOR quarterly CFO has dropped by -$3.75 million (-12.40%).
- XFOR quarterly CFO is now -505.29% below its all-time high of $8.40 million, reached on December 31, 2018.
Performance
XFOR Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$125.65 M
-$13.20 M-11.74%
September 30, 2024
Summary
- As of February 12, 2025, XFOR TTM cash flow from operations is -$125.65 million, with the most recent change of -$13.20 million (-11.74%) on September 30, 2024.
- Over the past year, XFOR TTM CFO has dropped by -$13.20 million (-11.74%).
- XFOR TTM CFO is now -3478.84% below its all-time high of -$3.51 million, reached on March 31, 2017.
Performance
XFOR TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
XFOR Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -25.2% | -12.4% | -11.7% |
| 3 y3 years | -64.1% | -12.4% | -11.7% |
| 5 y5 years | -279.7% | -166.5% | -161.5% |
XFOR Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -36.1% | at low | -84.2% | at low | -77.2% | at low |
| 5 y | 5-year | -100.8% | at low | -268.3% | at low | -161.5% | at low |
| alltime | all time | -792.3% | at low | -505.3% | at low | -3478.8% | at low |
X4 Pharmaceuticals Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$34.03 M(+12.4%) | -$125.65 M(+11.7%) |
| Jun 2024 | - | -$30.28 M(-9.9%) | -$112.45 M(+8.5%) |
| Mar 2024 | - | -$33.60 M(+21.1%) | -$103.60 M(+7.3%) |
| Dec 2023 | -$96.51 M(+25.2%) | -$27.75 M(+33.2%) | -$96.51 M(+9.8%) |
| Sep 2023 | - | -$20.83 M(-2.8%) | -$87.86 M(+1.8%) |
| Jun 2023 | - | -$21.43 M(-19.2%) | -$86.34 M(+3.5%) |
| Mar 2023 | - | -$26.51 M(+38.9%) | -$83.39 M(+8.1%) |
| Dec 2022 | -$77.10 M(+8.7%) | -$19.09 M(-1.1%) | -$77.10 M(+0.1%) |
| Sep 2022 | - | -$19.31 M(+4.5%) | -$77.06 M(+7.1%) |
| Jun 2022 | - | -$18.47 M(-8.7%) | -$71.97 M(-1.0%) |
| Mar 2022 | - | -$20.23 M(+6.2%) | -$72.69 M(+2.5%) |
| Dec 2021 | -$70.91 M(+20.5%) | -$19.05 M(+34.1%) | -$70.91 M(+2.2%) |
| Sep 2021 | - | -$14.21 M(-26.0%) | -$69.36 M(-0.2%) |
| Jun 2021 | - | -$19.20 M(+4.1%) | -$69.47 M(+12.5%) |
| Mar 2021 | - | -$18.44 M(+5.4%) | -$61.73 M(+5.0%) |
| Dec 2020 | -$58.82 M | -$17.50 M(+22.2%) | -$58.82 M(+16.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2020 | - | -$14.33 M(+25.0%) | -$50.55 M(+3.2%) |
| Jun 2020 | - | -$11.46 M(-26.2%) | -$49.00 M(-5.5%) |
| Mar 2020 | - | -$15.53 M(+68.0%) | -$51.83 M(+7.9%) |
| Dec 2019 | -$48.05 M(+89.0%) | -$9.24 M(-27.6%) | -$48.05 M(+58.0%) |
| Sep 2019 | - | -$12.77 M(-10.6%) | -$30.42 M(+17.9%) |
| Jun 2019 | - | -$14.29 M(+21.6%) | -$25.80 M(+3.2%) |
| Mar 2019 | - | -$11.75 M(-239.9%) | -$24.99 M(-1.7%) |
| Dec 2018 | -$25.42 M(-8.8%) | $8.40 M(-202.9%) | -$25.42 M(-45.6%) |
| Sep 2018 | - | -$8.16 M(-39.5%) | -$46.72 M(+7.0%) |
| Jun 2018 | - | -$13.48 M(+10.7%) | -$43.65 M(+19.5%) |
| Mar 2018 | - | -$12.18 M(-5.7%) | -$36.54 M(+31.1%) |
| Dec 2017 | -$27.87 M(+28.8%) | -$12.91 M(+153.6%) | -$27.87 M(+86.3%) |
| Sep 2017 | - | -$5.09 M(-20.0%) | -$14.96 M(+51.5%) |
| Jun 2017 | - | -$6.36 M(+81.2%) | -$9.87 M(+181.2%) |
| Mar 2017 | - | -$3.51 M | -$3.51 M |
| Dec 2016 | -$21.64 M(+100.1%) | - | - |
| Dec 2015 | -$10.82 M | - | - |
FAQ
- What is X4 Pharmaceuticals annual cash flow from operations?
- What is the all time high annual CFO for X4 Pharmaceuticals?
- What is X4 Pharmaceuticals annual CFO year-on-year change?
- What is X4 Pharmaceuticals quarterly cash flow from operations?
- What is the all time high quarterly CFO for X4 Pharmaceuticals?
- What is X4 Pharmaceuticals quarterly CFO year-on-year change?
- What is X4 Pharmaceuticals TTM cash flow from operations?
- What is the all time high TTM CFO for X4 Pharmaceuticals?
- What is X4 Pharmaceuticals TTM CFO year-on-year change?
What is X4 Pharmaceuticals annual cash flow from operations?
The current annual CFO of XFOR is -$96.51 M
What is the all time high annual CFO for X4 Pharmaceuticals?
X4 Pharmaceuticals all-time high annual cash flow from operations is -$10.82 M
What is X4 Pharmaceuticals annual CFO year-on-year change?
Over the past year, XFOR annual cash flow from operations has changed by -$19.41 M (-25.17%)
What is X4 Pharmaceuticals quarterly cash flow from operations?
The current quarterly CFO of XFOR is -$34.03 M
What is the all time high quarterly CFO for X4 Pharmaceuticals?
X4 Pharmaceuticals all-time high quarterly cash flow from operations is $8.40 M
What is X4 Pharmaceuticals quarterly CFO year-on-year change?
Over the past year, XFOR quarterly cash flow from operations has changed by -$3.75 M (-12.40%)
What is X4 Pharmaceuticals TTM cash flow from operations?
The current TTM CFO of XFOR is -$125.65 M
What is the all time high TTM CFO for X4 Pharmaceuticals?
X4 Pharmaceuticals all-time high TTM cash flow from operations is -$3.51 M
What is X4 Pharmaceuticals TTM CFO year-on-year change?
Over the past year, XFOR TTM cash flow from operations has changed by -$13.20 M (-11.74%)